Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

被引：1

作者：

Chihara, Dai ^{[1
]}

Arons, Evgeny ^{[2
]}

Stetler-Stevenson, Maryalice ^{[3
]}

Yuan, Constance M. ^{[3
]}

Wang, Hao-Wei ^{[3
]}

Zhou, Hong ^{[2
]}

Raffeld, Mark ^{[3
]}

Xi, Liqiang ^{[3
]}

Steinberg, Seth M. ^{[4
]}

Feurtado, Julie ^{[5
]}

James-Echenique, Lacey ^{[2
]}

Wilson, Wyndham ^{[6
]}

Braylan, Raul C. ^{[7
]}

Calvo, Katherine R. ^{[7
]}

Maric, Irina ^{[8
]}

Dulau-Florea, Alina ^{[7
]}

Kreitman, Robert J. ^{[2
]}

机构：

[1] NCI, Med Oncol Serv, NIH, Bethesda, MD 20892 USA

[2] NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA

[3] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA

[4] NCI, Biostat & Data Management Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[5] NCI, Off Res Nursing, NIH, Bethesda, MD 20892 USA

[6] NCI, Lymphoid Malignancies Branch, NIH, Bethesda, MD 20892 USA

[7] NIH, Hematol Sect, Dept Lab Med, Bldg 10, Bethesda, MD 20892 USA

[8] NIH, Dept Lab Med, Bldg 10, Bethesda, MD 20892 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124515

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1536

引用

页数：4

共 50 条

[1] Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
Chihara, Dai
Arons, Evgeny
Stetler-Stevenson, Maryalice
Yuan, Constance
Wang, Hao-Wei
Zhou, Hong
Raffeld, Mark
Xi, Liqiang
Steinberg, Seth M.
Feurtado, Julie
James-Echenique, Lacey
Tai, Chin-Hsien
Patel, Keyur P.
Braylan, Raul C.
Calvo, Katherine R.
Maric, Irina
Dulau-Florea, Alina
Kreitman, Robert J.
BLOOD ADVANCES, 2021, 5 (23) : 4807 - 4816
[2] Long-term update of a phase II on the interest of rituximab with cladribine in the variant form of hairy cell leukemia
Cailly, Laura
Tomowiak, Cecile
HEMATOLOGIE, 2022, 28 (01): : 10 - 12
[3] Long-term follow-up of patients with hairy cell leukemia after cladribine treatment
Saven, A
Burian, C
Koziol, JA
Piro, LD
BLOOD, 1998, 92 (06) : 1918 - 1926
[4] Long term follow-up of patients with hairy cell leukemia (HCL) following cladribine treatment.
Saven, A
Burian, C
Koziol, J
Piro, L
BLOOD, 1997, 90 (10) : 2573 - 2573
[5] Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia
Chihara, Dai
Arons, Evgeny
Stetler-Stevenson, Maryalice
Yuan, Constance M.
Wang, Hao-Wei
Zhou, Hong
Raffeld, Mark
Xi, Liqiang
Steinberg, Seth M.
Feurtado, Julie
James, Lacey
Wilson, Wyndham
Braylan, Raul C.
Calvo, Katherine R.
Maric, Irina
Dulau-Florea, Alina
Kreitman, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) : 1527 - +
[6] Long term follow-up of hairy cell leukemia (HCL) treated with of pentostatin and/or cladribine.
Ruchlemer, R
Swansbury, GJ
Hilditch, BL
Matutes, E
Catovsky, D
BLOOD, 2002, 100 (11) : 777A - 777A
[7] Long term follow-up of patients with hairy cell leukemia (HCL).
Ravandi-Kashani, F
Kantarjian, H
Faderl, S
O'Brien, S
Thomas, D
Koller, C
Cortes, J
Pierce, S
Keating, M
Estey, E
BLOOD, 2004, 104 (11) : 946A - 947A
[8] Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia
Kreitman, Robert J.
Wilson, Wyndham
Calvo, Katherine R.
Arons, Evgeny
Roth, Laura
Sapolsky, Jeffrey
Zhou, Hong
Raffeld, Mark
Stetler-Stevenson, Maryalice
CLINICAL CANCER RESEARCH, 2013, 19 (24) : 6873 - 6881
[9] Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy
Juliusson, Gunnar
Samuelsson, Henrik
LEUKEMIA & LYMPHOMA, 2011, 52 : 46 - 49
[10] Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up
Hoffman, MA
Janson, D
Rose, E
Rai, KR
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 1138 - 1142

← 1 2 3 4 5 →